Cellzome licenses Episphere to GlaxoSmithKline
Less than two years after receiving an option to Cellzome AG's anti-inflammatory kinase inhibitors, GlaxoSmithKline PLC is working with the chemical proteomics company again. This time the Big Pharma has received exclusive rights to Cellzome's Episphere epigenetics platform for development of immuno-inflammation therapeutics.
Drug Discovery Tools
- Drug Discovery Tools
- Includes Equity
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com